Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Wassim, Abida"'
Autor:
Charlotte S. Walmsley, Philip Jonsson, Michael L. Cheng, Sean McBride, Christopher Kaeser, Herbert Alberto Vargas, Vincent Laudone, Barry S. Taylor, Rajya Kappagantula, Priscilla Baez, Allison L. Richards, Anne Marie Noronha, Dilmi Perera, Michael Berger, David B. Solit, Christine A. Iacobuzio-Donahue, Howard I. Scher, Mark T. A. Donoghue, Wassim Abida, Alison M. Schram
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract Reversion mutations that restore wild-type function of the BRCA gene have been described as a key mechanism of resistance to Poly(ADP-ribose) polymerase (PARP) inhibitor therapy in BRCA-associated cancers. Here, we report a case of a patient
Externí odkaz:
https://doaj.org/article/13584368662940d8a5e228080b67724c
Autor:
Daniel Vargas P. de Almeida, Justine M. Anderson, Daniel C. Danila, Michael J. Morris, Susan F. Slovin, Wassim Abida, Erica D. Cohn, Raymond E. Baser, Howard I. Scher, Karen A. Autio
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 162-169 (2023)
Introduction: Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of life, and longer survival. Limite
Externí odkaz:
https://doaj.org/article/31114f0b1c6d4458be476309142a3dfb
Publikováno v:
Current Oncology, Vol 29, Iss 6, Pp 4178-4184 (2022)
PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC ass
Externí odkaz:
https://doaj.org/article/c16696233a7a45dda11691fcfdfe6d10
Autor:
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard A. Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida, Alexander Drilon, Ping Chi, Sandra P. D’ Angelo, Mark A. Dickson, Mary Lou Keohan, Ciara M. Kelly, Mark Agulnik, Sant P. Chawla, Edwin Choy, Rashmi Chugh, Christian F. Meyer, Parvathi A. Myer, Jessica L. Moore, Ross A. Okimoto, Raphael E. Pollock, Vinod Ravi, Arun S. Singh, Neeta Somaiah, Andrew J. Wagner, John H. Healey, Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Comprehensive molecular profiles are required to understand and treat sarcomas, which comprise more than 70 different subtypes. Here, the authors profile the genomic landscape of 7494 sarcomas across 44 histologies using targeted panel sequencing and
Externí odkaz:
https://doaj.org/article/ded28dd2538e4114ba7de3e78b153f38
Autor:
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T. A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao, Margaret H. Reynolds, Sarah M. Phillips, Tara Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
How different oncogenic Akt mutants can affect the response to Akt inhibitors is currently unclear. Here, the authors analyse somatic mutations of Akt1-3 isoforms in several human cancers, investigate their oncogenic effects and therapeutic relevance
Externí odkaz:
https://doaj.org/article/2f4ee7e6727f4b59871619d4a10453d0
Autor:
A. Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova, Yu Hu, Fanli Meng, Mohammad Haque, Justyna Sadowska, Brian J. Murphy, Tessara Baldi, Ian Johnson, Ryan Ptashkin, Maysun Hasan, Preethi Srinivasan, Anoop Balakrishnan Rema, Ivelise Rijo, Aaron Agarunov, Helen Won, Dilmi Perera, David N. Brown, Aliaksandra Samoila, Xiaohong Jing, Erika Gedvilaite, Julie L. Yang, Dennis P. Stephens, Jenna-Marie Dix, Nicole DeGroat, Khedoudja Nafa, Aijazuddin Syed, Alan Li, Emily S. Lebow, Anita S. Bowman, Donna C. Ferguson, Ying Liu, Douglas A. Mata, Rohit Sharma, Soo-Ryum Yang, Tejus Bale, Jamal K. Benhamida, Jason C. Chang, Snjezana Dogan, Meera R. Hameed, Jaclyn F. Hechtman, Christine Moung, Dara S. Ross, Efsevia Vakiani, Chad M. Vanderbilt, JinJuan Yao, Pedram Razavi, Lillian M. Smyth, Sarat Chandarlapaty, Gopa Iyer, Wassim Abida, James J. Harding, Benjamin Krantz, Eileen O’Reilly, Helena A. Yu, Bob T. Li, Charles M. Rudin, Luis Diaz, David B. Solit, Maria E. Arcila, Marc Ladanyi, Brian Loomis, Dana Tsui, Michael F. Berger, Ahmet Zehir, Ryma Benayed
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Liquid biopsies allow the non-invasive detection of somatic mutations from tumours. Here, the authors develop and test MSK-ACCESS, an NGS-based clinical assay for identifying low frequency mutations in 129 genes and describe how it benefits patients
Externí odkaz:
https://doaj.org/article/ca7c61a9651341a5819f1ee6a4c47bfa
Autor:
Dana W. Y. Tsui, Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis Stephens, Helen Won, Preethi Srinivasan, Kety Huberman, Fanli Meng, Xiaohong Jing, Juber Patel, Maysun Hasan, Ian Johnson, Erika Gedvilaite, Brian Houck-Loomis, Nicholas D. Socci, S. Duygu Selcuklu, Venkatraman E. Seshan, Hongxin Zhang, Debyani Chakravarty, Ahmet Zehir, Ryma Benayed, Maria Arcila, Marc Ladanyi, Samuel A. Funt, Darren R. Feldman, Bob T. Li, Pedram Razavi, Jonathan Rosenberg, Dean Bajorin, Gopa Iyer, Wassim Abida, Howard I. Scher, Dana Rathkopf, Agnes Viale, Michael F. Berger, David B. Solit
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-15 (2021)
Abstract Background Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulatin
Externí odkaz:
https://doaj.org/article/a175329a098b4151983ca7a727781ce0
Autor:
Kelsey E. Breen, Heather Symecko, Kelsey Spielman, Rebecca Gebert, Ibrahim H. Shah, Stacy Pundock, Melissa Batson, Vivek K. Narayan, Zsofia K. Stadler, Karen A. Autio, Wassim Abida, Daniel C. Danila, Howard I. Scher, Michael J. Morris, Jada G. Hamilton, Mark E. Robson, Susan M. Domchek, Maria I. Carlo
Publikováno v:
Journal of Urology. 209:918-927
Autor:
Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H. Bryce, Daniel Castellano, Albert Font, Jeremy Shapiro, Jingsong Zhang, Brieuc Sautois, Nicholas J. Vogelzang, Gurkamal Chatta, Kevin Courtney, Andrea Harzstark, Francesco Ricci, Darrin Despain, Simon Watkins, Charmin King, Minh Nguyen, Andrew D. Simmons, Simon Chowdhury, Wassim Abida
Publikováno v:
European Urology. 83:200-209
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion mutations are a k
Autor:
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel R. Gingerich, Elias Pintus, Srikala S. Sridhar, Richard M. Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, John Staffurth, Charles Redfern, María I. Sáez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine A. Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce
Publikováno v:
New England Journal of Medicine. 388:719-732